{
    "2020-04-03": [
        [
            {
                "time": "",
                "original_text": "沃森生物 研发资本化率超高",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "研发",
                        "资本化率"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "为何服务收入大幅下降？沃森生物收年报问询函 盈利能力下降",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "服务收入",
                        "盈利能力",
                        "年报",
                        "问询函"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国产“疫苗之王”沃森生物奇葩事情多：第一二大股东魔术退位之争或从深交所11问中找到答案",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "疫苗",
                        "大股东",
                        "深交所",
                        "问询"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物年报遭深交所11问 营收11亿应收账款近6亿 问询",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "年报",
                        "深交所",
                        "营收",
                        "应收账款",
                        "问询"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国产“沛儿”获批上市，将与辉瑞争夺市场",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "沛儿",
                        "获批上市",
                        "辉瑞",
                        "市场竞争"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "沃森生物年报收深交所11问 销售收入与批签发量变动不一致遭质疑",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "年报",
                        "深交所",
                        "销售收入",
                        "批签发量",
                        "质疑"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}